🇺🇸 FDA
Pipeline program

VX-670 Solution for Injection/Infusion, 0.9% saline solution (w/v)

VX23-670-001

Phase 2 small_molecule active

Quick answer

VX-670 Solution for Injection/Infusion, 0.9% saline solution (w/v) for Myotonic Dystrophy is a Phase 2 program (small_molecule) at Vertex Pharmaceuticals (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Vertex Pharmaceuticals (Ireland) Limited
Indication
Myotonic Dystrophy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials